scholarly journals Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line

2013 ◽  
Vol 169 (1) ◽  
pp. 21-33 ◽  
Author(s):  
C Fahrmayr ◽  
J König ◽  
D Auge ◽  
M Mieth ◽  
K Münch ◽  
...  
2021 ◽  
Vol 22 (12) ◽  
pp. 6566
Author(s):  
Martina Tremmel ◽  
Josef Kiermaier ◽  
Jörg Heilmann

Several medical plants, such as Passiflora incarnata L., contain C-glycosylated flavonoids, which may contribute to their efficacy. Information regarding the bioavailability and metabolism of these compounds is essential, but not sufficiently available. Therefore, the metabolism of the C-glycosylated flavones orientin, isoorientin, schaftoside, isoschaftoside, vitexin, and isovitexin was investigated using the Caco-2 cell line as an in vitro intestinal and epithelial metabolism model. Isovitexin, orientin, and isoorientin showed broad ranges of phase I and II metabolites containing hydroxylated, methoxylated, and sulfated compounds, whereas schaftoside, isoschaftoside, and vitexin underwent poor metabolism. All metabolites were identified via UHPLC-MS or UHPLC-MS/MS using compound libraries containing all conceivable metabolites. Some structures were confirmed via UHPLC-MS experiments with reference compounds after a cleavage reaction using glucuronidase and sulfatase. Of particular interest is the observed cleavage of the C–C bonds between sugar and aglycone residues in isovitexin, orientin, and isoorientin, resulting in unexpected glucuronidated or sulfated luteolin and apigenin derivatives. These findings indicate that C-glycosidic flavones can be highly metabolized in the intestine. In particular, flavonoids with ortho-dihydroxy groups showed sulfated metabolites. The identified glucuronidated or sulfated aglycones demonstrate that enzymes expressed by Caco-2 cells are able to potentially cleave C–C bonds in vitro.


2005 ◽  
Author(s):  
Alvin J. Banguilan ◽  
John S. Cable ◽  
Charles E. Cantley ◽  
Leslie Raymer ◽  
Victoria Dabir-Banguilan

2021 ◽  
Vol 22 (2) ◽  
pp. 813
Author(s):  
Isabel Fernandes ◽  
Cecília Melo-Alvim ◽  
Raquel Lopes-Brás ◽  
Miguel Esperança-Martins ◽  
Luís Costa

Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.


2010 ◽  
Vol 33 (9) ◽  
pp. 999-1005 ◽  
Author(s):  
Richard Harrop ◽  
William Shingler ◽  
Michelle Kelleher ◽  
Jackie de Belin ◽  
Peter Treasure

Author(s):  
LAURA MUFSON ◽  
DONNA MOREAU ◽  
MYRNA M. WEISSMAN ◽  
PRIYA WICKRAMARATNE ◽  
JACQUELINE MARTIN ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document